Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter

Molecular Endocrinology

Volumn 13, Issue 3, 1999, Pages 376-384

  Lu, Shan ^a   Liu, Min ^a   Epner, Daniel E ^a   Tsai, Sophia Y ^a   Tsai, Ming Jer ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P21;

APOPTOSIS; ARTICLE; CELL GROWTH; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HORMONAL REGULATION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; SEQUENCE ANALYSIS;

EID: 0032913866     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.13.3.0254     Document Type: Article

References (41)

1. 1. Hunter T, Pines J 1994 Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79:573-582
2. 2. Serrano M, Hannon GJ, Beach D 1993 A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707
3. 3. Hannon GJ, Beach D 1994 p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371:257-261
4. 4. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG, Xiong Y 1994 Growth suppression by p18, a P16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8:2939-2952
5. 5. Chan FKM, Zhang J, Cheng L, Shapiro DN, Winoto A 1995 Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. Mol Cell Biol 15:2682-2688
6. 6. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA 1994 Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756
7. 7. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day Sr R, Johnson BE, Skolnick MH 1994 A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440
8. 8. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J 1995 Retinoblastomaprotein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 375:503-506
9. 9. Koh J, Enders GH, Dynlacht BD, Harlow E 1995 Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375:506-510
10. 10. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ 1993 The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816
11. 11. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B 1993 WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
12. 12. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D 1993 p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704
13. 13. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J 1994 Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66
14. 14. Toyoshima H, Hunter T 1994 p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67-74
15. 15. Lee MH, Reynisdottir I, Massague J 1995 Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9:639-649
16. 16. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ 1995 p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650-662
17. 17. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ 1995 p53-independent expression of p21 Cip1 in muscle and other terminally differentiating cells. Science 267:1024-1027
18. 18. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB 1995 Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267:1018-1021
19. 19. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y 1987 The endocrinology and developmental biology of the prostate. Endocr Rev 8:338-362
20. 20. Berges RR, Furuya Y, Remington L, English HF, Jacks T, Isaacs JT 1993 Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci USA 90:8910-8914
21. 21. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF 1992 Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl 13:457-464
22. 22. Mooradian AD, Morley JE, Korenman SG 1987 Biological actions of androgens. Endocr Rev 8:1-28
23. 23. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J 1991 The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 5:1921-1930
24. 24. Tan JA, Marschke KB, Ho KC, Perry ST, Wilson EM, French FS 1992 Response elements of the androgen-regulated C3 gene. J Biol Chem 267:4456-4466
25. 25. Adler AJ, Scheller A, Hoffman Y, Robins DM 1991 Multiple components of a complex androgen-dependent enhancer. Mol Endocrinol 5:1587-1596
26. 26. Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoek R, Hamel A, Bock ME, MacDonald BS, Nickel BE, Chang C, Liao S, Cattini PA, Matusik RJ 1993 Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 7:23-36
27. 27. Lu S, Tsai SY, Tsai MJ 1997 Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 57:4511-4516
28. 28. Lu S, Saydak M, Gentile V, Stein JP, Davies PJA 1995 Isolation and characterization of the human tissue transglutaminase gene promoter. J Biol Chem 270:9748-9756
29. 29. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP 1996 Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142-153
30. 30. Datto MB, Yu Y, Wang XF 1995 Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem 270:28623-28628
31. 31. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY 1996 Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272:719-722
32. 32. Prabhu S, Ignatova A, Park ST, Sun XH 1997 Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins. Mol Cell Biol 17:5888-5896
33. 33. Levine AJ 1997 p53, the cellular gatekeeper for growth and division. Cell 88:323-331
34. 34. Wang J, Walsh K 1996 Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273:359-361
35. 35. Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ 1997 p21Waf1/Cip1 protects against p53-mediated apoptosis of human melanoma cells. Oncogene 14:929-935
36. 36. Li R, Waga S, Hannon GJ, Beach D, Stillman B 1994 Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534-537
37. 37. Poluha W, Poluha DK, Chang B, Crosbie NE, Schonhoff CM, Kilpatrick DL, Ross AH 1996 The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol Cell Biol 16:1335-1341
38. 38. Chen X, Ko LJ, Jayaraman L, Prives C 1996 p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10:2438-2451
39. 39. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R 1995 Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438-4445
40. 40. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM, Campbell ML 1992 Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944
41. 41. Murtha P, Tindall DJ, Young CYF 1993 Androgen induction of a human prostate -specific kallikrein, hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry 32:6459-6464